Details

Autor(en) / Beteiligte

• Werner, Ricardo N.
• Gaskins, Matthew
• Avila Valle, Gabriela
• Budach, Volker
• Koswig, Stephan
• Mosthaf, Franz A.
• Raab, Hans-Rudolf
• Rödel, Claus
• Nast, Alexander
• Siegel, Robert
• Aigner, Felix

Titel

State of the art treatment for stage I to III anal squamous cell carcinoma: A systematic review and meta-analysis

Ist Teil von

• Radiotherapy and oncology, 2021-04, Vol.157, p.188-196

Ort / Verlag

Ireland: Elsevier B.V

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• •Critically appraised data from controlled studies of interventions for anal cancer.•We identified only weak evidence for the treatment of early stages.•We included a series of RCTs in which modalities of chemoradiation were assessed.•More recent approaches (eg immune therapies) not yet evaluated in controlled studies.•GRADE evaluations may help clinicians and their patients take informed decisions. This systematic review summarised and critically appraised evidence on the efficacy and safety of interventions for anal cancer to support the panel of experts developing the national evidence-based anal cancer guideline in Germany. We conducted a systematic review and meta-analyses of interventions for the treatment of stage I to III anal squamous cell carcinoma (SCCA). We systematically searched several databases and included any randomised controlled trial (RCT) assessing the pre-specified patient populations, regardless of the interventions studied. Non-randomised controlled studies of selected, pre-specified interventions were included if RCTs were not available or contained insufficient information. Where possible, we conducted meta-analyses and critically assessed confidence in the effect estimates using the GRADE approach. Our searches yielded 10,325 (25 October 2018) and 889 hits (update search on 18 July 2019). Among the 41 studies (47 publications) included, we identified 19 comparisons of interventions for SCCA, and confidence in the effect estimates ranged from very low to high. Most RCTs compared various chemoradiation regimes. For other treatment options, such as local excision in early stages or different radiotherapies, we mostly identified comparative cohort studies. Our findings indicate that, in most clinical situations, primary chemoradiation based on 5-FU and MMC is still the gold standard. However, treatment options for stage I anal cancer, particularly of the anal margin, as well as newer treatment approaches should be investigated in future RCTs. Overall, our findings may help health care professionals and patients make informed decisions about treatment choices.